Temedica

About Temedica

Temedica is a digital health company founded in 2016 in Munich, Germany, by Gloria Seibert and Benjamin Friedrich. Gloria Seibert, the CEO, was motivated to start the company due to her grandfather's battle with multiple sclerosis, which highlighted the need for more personalized patient support. Before Temedica, she worked as a business consultant at McKinsey and studied software engineering in Silicon Valley to gain the necessary technological expertise. Co-founder and Chief Medical Officer, PD Dr. med Benjamin Friedrich, brings extensive medical and academic experience from his work in radiology and neuroradiology at institutions like the Technical University of Munich.

The company operates a health insights ecosystem designed to centralize and analyze health data from various sources to generate real-world evidence. This ecosystem serves a wide range of clients, including pharmaceutical companies, research institutions, healthcare professionals, and patients. Temedica's business model is centered on partnerships with pharmaceutical firms, providing them with anonymized, GDPR-compliant data that offers insights into disease progression, patient journeys, and treatment effectiveness outside of traditional clinical trials. Partners have included major companies like Roche and AbbVie Germany.

Temedica's core offerings include digital patient companion apps and the Permea real-world insights platform. The companion apps are designed for patients with chronic conditions such as multiple sclerosis, psoriasis, and cancer, offering personalized guidance and support. The Permea platform integrates patient-generated data from these apps with other sources like registry and insurance data to provide a comprehensive view of patient care realities. This allows clients to receive customized analytics and reports that inform strategic decisions in areas like product development, market strategy, and patient engagement. The company has raised a total of $44.6 million in funding, including a Series B round that closed in November 2022.